When Breast Cancer Tries to Grow Its Own Pantry

What ingredient does a hungry breast tumor sometimes order before the chef even turns on the stove? Blood vessels.

That sounds rude, but it is also biology. Tumors need oxygen and nutrients, so they coax the body into building little supply lines, a process called angiogenesis. Think of it as a cancerous casserole demanding a private grocery delivery service. The new study by Ding and colleagues asks a practical kitchen-table question: if chemotherapy is the main heat, could blocking those supply lines help the dish cook more thoroughly before surgery? The paper tested anlotinib plus chemotherapy before surgery in high-risk HR+/HER2- breast cancer, the most common breast cancer subtype and often a stubborn one in the pre-surgery setting.¹

The Stubborn Stew

HR+/HER2- breast cancer usually has hormone receptors, meaning estrogen or progesterone can help feed its growth. It does not have extra HER2, so the HER2-targeted recipe book does not apply. That leaves doctors choosing among surgery, endocrine therapy, chemotherapy, radiation, and newer targeted drugs depending on the case.

Before surgery, treatment is called neoadjuvant therapy. It is basically a pre-bake taste test: give treatment first, then see how much cancer is left when the surgeon removes the tumor. In some breast cancers, especially triple-negative and HER2-positive disease, a pathologic complete response, or pCR, can happen more often and often signals a better outlook. HR+/HER2- tumors, however, are famous for saying, "Thanks, but I brought my own lunch." Their pCR rates after standard neoadjuvant chemotherapy tend to be lower, and reviews keep circling the same headache: how do we pick the right pre-surgery recipe for the right patient?²

Meet Anlotinib, the Pantry Lock

Anlotinib is an oral tyrosine kinase inhibitor. Translation: it blocks several growth-signal switches, including VEGFR, PDGFR, FGFR, and c-Kit. The VEGF/VEGFR pathway is a major way tumors encourage new blood-vessel growth, and anti-angiogenic treatment has been studied for decades.³ Earlier anti-vessel strategies in breast cancer, especially bevacizumab, sometimes improved response rates but did not reliably improve survival and added toxicity. So the field has been cautious, which is scientist-speak for "we burned that sauce once and nobody forgot."

This trial used anlotinib with nab-paclitaxel, pirarubicin, and cyclophosphamide in patients with stage II-III HR+/HER2- breast cancer and a high Ki-67 index. Ki-67 is a marker of how many cancer cells are actively dividing, like counting how many cooks in the kitchen are frantically chopping onions.

What Came Out of the Oven

The study enrolled 31 patients. Twenty-eight completed treatment and surgery. In that per-protocol group, 4 of 28 patients, or 14.3%, had total pCR, meaning no invasive cancer was found in the breast or axillary lymph nodes. Seven of 28, or 25.0%, had residual cancer burden class 0 or I, a low-leftover category that sounds like a fridge-cleaning victory because, in a way, it is.¹

Scans showed tumors shrank in many patients: the objective response rate was 93.5%. But the authors also found that imaging response did not neatly match what pathology later found under the microscope. In kitchen terms, the cake can look done from the window and still be gooey in the middle. Pathology remains the toothpick test.

The most interesting clue involved blood vessels. Patients whose tumors started with higher VEGFR2 expression and higher microvessel density were more likely to have better pathological responses. After treatment, Ki-67, VEGFR2, and microvessel density dropped. That supports the idea that some tumors may be especially dependent on their vascular pantry, and those may be the ones most likely to notice when anlotinib locks the cupboard.

The researchers also compared results with a real-world chemotherapy-only cohort using statistical weighting. After balancing baseline features, the anlotinib group had higher chances of total pCR, low residual cancer burden, and breast pCR. Helpful? Yes. Final proof? Not yet. This was not a randomized phase III trial, so we should not serve it as the main course just yet.

The Fine Print on the Recipe Card

Safety mattered here because neoadjuvant treatment aims for cure, not just temporary tumor shrinkage. Common side effects included hair loss, low white blood cells, nausea or vomiting, and neutropenia. Anlotinib-linked effects included hypertension, hand-foot syndrome, protein in the urine, and headache. Most were manageable, though one patient stopped trial therapy after grade 4 neutropenia and leukopenia.¹

The limitations are real: single center, single arm, small sample, post-hoc biomarker work, and short follow-up for a cancer subtype where late recurrence can matter. Also, some drugs in the regimen are not used everywhere, so the exact recipe may not transfer cleanly to every hospital kitchen.

Still, the study offers a useful idea: HR+/HER2- breast cancer may not be one big casserole. Some tumors may be more vessel-hungry than others. If future randomized trials confirm this, doctors might use VEGFR2 or microvessel density to decide who should get an anti-angiogenic add-on and who can skip the extra seasoning.

That would be the real win: less guessing, better matching, and fewer patients stuck with a treatment recipe that smells impressive but does not actually feed the goal.

References

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.